Display options
Cite
van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med. 2019;25(6):666-673doi: 10.1097/MCP.0000000000000625.
van der Meer, R., Touw, D. J., & Heijerman, H. G. M. (2019). Prevention of drug-related complications in cystic fibrosis. Current opinion in pulmonary medicine, 25(6), 666-673. https://doi.org/10.1097/MCP.0000000000000625
van der Meer, Renske, et al. "Prevention of drug-related complications in cystic fibrosis." Current opinion in pulmonary medicine vol. 25,6 (2019): 666-673. doi: https://doi.org/10.1097/MCP.0000000000000625
van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625. PMID: 31503211.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625.

Prevention of drug-related complications in cystic fibrosis.

Current opinion in pulmonary medicine

Renske van der Meer, Daan J Touw, Harry G M Heijerman

Affiliations

  1. Department of Pulmonology, Haga Teaching Hospital, The Hague.
  2. Faculty of Pharmaceutical Sciences, University Medical Center Groningen, Groningen.
  3. Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 31503211 DOI: 10.1097/MCP.0000000000000625

Abstract

PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survival of patients with cystic fibrosis has changed dramatically. Recently, targeted therapy of cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become available. Despite these promising developments, treatment of this complex multiorgan disease constitutes a high and variable amount of other drugs. Complications of pharmacotherapeutic treatment are, therefore, expected to become more prevalent. This gives cause to review drug-related side effects in this new era in cystic fibrosis treatment.

RECENT FINDINGS: We will discuss cystic fibrosis-related pharmacotherapies with a focus on indication of treatment, side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity. Many recent publications about pharmacotherapy in cystic fibrosis, focus on antifungal therapy and CFTR modulators. We will give an overview of the most important studies.

SUMMARY: With increased life expectancy which is, in part, because of better treatment options, the burden of pharmacotherapy in cystic fibrosis patients will increase. This has a high impact on quality of life as pharmacotherapy is time consuming and may cause side effects. Therefore, it is very important to be aware of possible pharmacotherapy-related side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity.

MeSH terms

Publication Types